Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1

Biomedicine and Pharmacotherapy

Volumn 66, Issue 1, 2012, Pages 70-75

  Dong, X L ^a   Xu, P F ^b   Miao, C ^b   Fu, Z Y ^b   Li, Q P ^b   Tang, P Y ^b   Wang, T ^b  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cyclin B1; Hypoxia; Paclitaxel

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN B1; PACLITAXEL; TUBULIN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL STRAIN MCF 7; CHEMOSENSITIVITY; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CYCLIN B1; DRUG RESISTANCE, NEOPLASM; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; PACLITAXEL; TUBULIN; TUBULIN MODULATORS;

EID: 84862792043     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.11.016     Document Type: Article

References (30)

1. Cortesi L., Chiuri V.E., Ruscelli S., Bellelli V., Negri R., Rashid I., et al. Prognosis of screen-detected breast cancers: results of a population-based study. BMC Cancer 2006, 6:17.
2. Gerend M.A., Pai M. Social determinants of Black-White disparities in breast cancer mortality: a review. Cancer Epidemiol Biomarkers Prev 2008, 17:2913-2923.
3. Dang D.T., Chun S.Y., Burkitt K., Abe M., Chen S., Havre P., et al. Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition. Cancer Res 2008, 68:1872-1880.
4. Mizukami Y., Kohgo Y., Chung D.C. Hypoxia-inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res 2007, 13:5670-5674.
5. Hiraga T., Kizaka-Kondoh S., Hirota K., Hiraoka M., Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 2007, 67:4157-4163.
6. Erler J.T., Cawthorne C.J., Williams K.J., Koritzinsky M., Wouters B.G., Wilson C., et al. Hypoxia-mediated downregulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004, 24:2875-2889.
7. Baek J.H., Jang J.E., Kang C.M., Chung H.Y., Kim N.D., Kim K.W. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene 2000, 19:4621-4631.
8. Park S.Y., Billiar T.R., Seol D.W. Hypoxia inhibition of apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Biochem Biophys Res Commun 2002, 291:150-153.
9. Yokoi K., Fidler I.J. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 2004, 10:2299-2306.
10. Helczynska K., Larsson A.M., Holmquist Mengelbier L., Bridges E., Fredlund E., Borgquist S., et al. Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res 2008, 68:9212-9220.
11. Pathan N., Aime-Sempe C., Kitada S., Basu A., Haldar S., Reed J.C. Microtubule-targeting drugs induce bcl-2 phosphorylation and association with Pin1. Neoplasia 2001, 3:550-559.
12. Perkins C.L., Fang G., Kim C.N., Bhalla K.N. The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res 2000, 60:1645-1653.
13. Shiah S.G., Chuang S.E., Kuo M.L. Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells. Mol Pharmacol 2001, 59:254-262.
14. Janssen K., Pohlmann S., Janicke R.U., Schulze-Osthoff K., Fischer U. Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment. Blood 2007, 110:3662-3672.
15. Yuan J., Yan R., Kramer A., Eckerdt F., Roller M., Kaufmann M., et al. Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene 2004, 23:5843-5852.
16. Xie X.H., An H.J., Kang S., Hong S., Choi Y.P., Kim Y.T., et al. Loss of cyclin B1 followed by downregulation of cyclin A/Cdk2, apoptosis and antiproliferation in Hela cell line. Int J Cancer 2005, 116:520-525.
17. Gomez L.A., de Las Pozas A., Reiner T., Burnstein K., Perez-Stable C. Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy. Mol Cancer Ther 2007, 6:1534-1543.
18. Zaffaroni N., Silvestrini R., Orlandi L., Bearzatto A., Gornati D., Villa R. Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and resistant human ovarian cells. Br J Cancer 1998, 77:1378-1385.
19. Wang T., Lv J.H., Zhang X.F., Li C.J., Han X., Sun Y.J. Tissue inhibitor of metalloproteinase-1 protects MCF-7 breast cancer cells from paclitaxel-induced apoptosis by decreasing the stability of cyclin B1. Int J Cancer 2010, 126:362-370.
20. Brown N.S., Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001, 3:323-327.
21. Sullivan R., Pare G.C., Frederiksen L.J., Semenza G.L., Graham C.H. Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther 2008, 7:1961-1973.
22. Viola R.J., Provenzale J.M., Li F., Li C.Y., Yuan H., Tashjian J., et al. In vivo bioluminescence imaging monitoring of hypoxia-inducible factor 1alpha, a promoter that protects cells, in response to chemotherapy. AJR Am J Roentgenol 2008, 191:1779-1784.
23. Wen W., Ding J., Sun W., Wu K., Ning B., Gong W., et al. Suppression of cyclin D1 by hypoxia-inducible factor-1 via direct mechanism inhibits the proliferation and 5-fluorouracil-induced apoptosis of A549 cells. Cancer Res 2010, 70:2010-2019.
24. Bindra R.S., Vasselli J.R., Stearman R., Linehan W.M., Klausner R.D. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 2002, 62:3014-3019.
25. Tong Q., Zheng L., Lin L., Li B., Wang D., Li D. Hypoxia-induced mitogenic factor promotes vascular adhesion molecule-1 expression via the PI-3K/Akt-NF-kappaB signaling pathway. Am J Respir Cell Mol Biol 2006, 35:444-456.
26. Li Y.M., Zhou B.P., Deng J., Pan Y., Hay N., Hung M.C. A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3-kinase/Akt in HER2 overexpressing cells. Cancer Res 2005, 65:3257-3263.
27. Cho M.K., Suh S.H., Lee C.H., Kim S.G. Bovine type I collagen inhibits Raw264.7 cell proliferation through phosphoinositide 3-kinase- and mitogen-activated protein kinase-dependent downregulation of cyclins D1, A and B1. Biochim Biophys Acta 2005, 1744:47-57.
28. Knuefermann C., Lu Y., Liu B., Jin W., Liang K., Wu L., et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003, 22:3205-3212.
29. Clark A.S., West K., Streicher S., Dennis P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002, 1:707-717.
30. Russo A.J., Magro P.G., Hu Z., Li W.W., Peters R., Mandola J., et al. E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents. Cancer Res 2006, 66:7253-7260.